

**REMARKS**

In response to the Restriction Requirement dated January 13, 2003, Applicant hereby wishes to elect, with traverse, the subject matter of Group III (claims 55-60) for continued prosecution in this application. As suggested by the examiner, the inventorship is also being amended in view of the election of Group III. MICHAEL J. HELLER, RICHARD R. ANDERSON, DONALD E. ACKLEY, and TINA S. NOVA have been removed because their invention is no longer being claimed in this application.

With respect to the requirement for an election of species, Applicant elects the following species with respect to Group III:

- A. Species of expected biological response – binding;
- B. Ultimate species of known substrate (i.e. chemical structure) – acetyl choline;
- C. Species of response profile – emission of electromagnetic waves, e.g., emission of fluorescence;
- D. Ultimate species of test substrate – analogs of acetyl choline, e.g., antagonists of acetyl choline, e.g., atropine; and
- E. Species of molecular descriptor array - (i) ligand binding component – peptide; (ii) first and second programmable pairing component – pRNA.

With respect to species D alone, Applicant notes that the species of test substrate is, by definition, an unknown – that is why the substrate is being tested. Therefore, it would be inappropriate, and fundamentally contradictory to the purpose of the invention, to limit the test substrate to a single species.

Applicant notes that all of dependent claims 57-60 should remain pending since claim 56 is generic with respect to any particular species. This election is being made without traverse and without prejudice to continue prosecution of those claims in a later application. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

Respectfully submitted,

O'MELVENY & MYERS LLP

Dated: March 13, 2003

By: John Kappos  
John Kappos  
Reg. No. 37,861

JCK/DKW/dnd



34263

PATENT TRADEMARK OFFICE

O'Melveny & Myers LLP  
114 Pacifica, Suite 100  
Irvine, CA 92618-3315  
(949) 737-2900

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

56. (Amended) A method for drug discovery comprising the steps of:
- providing a molecular descriptor array having a plurality of definable locations,
  - providing a ~~drug~~ pharmaceutically active compound to the molecular descriptor array, and monitoring the response of the molecular descriptor array to the ~~drug~~ pharmaceutically active compound, thereby developing a response profile for the ~~drug~~ pharmaceutically active compound,
  - subsequently providing in series related compounds to the molecular descriptor array, monitoring the response of the molecular descriptor array to the related compounds, thereby developing further response profiles for the related compounds, and
  - providing a test compound to the molecular descriptor array, monitoring the response of the molecular descriptor arrays to the test compound and analyzing the response of the test compound relative to the response profiles for the ~~drug~~ pharmaceutically active compound and related compounds so as to predict expected response of the test compound.